JP2025512469A5 - - Google Patents
Info
- Publication number
- JP2025512469A5 JP2025512469A5 JP2024560676A JP2024560676A JP2025512469A5 JP 2025512469 A5 JP2025512469 A5 JP 2025512469A5 JP 2024560676 A JP2024560676 A JP 2024560676A JP 2024560676 A JP2024560676 A JP 2024560676A JP 2025512469 A5 JP2025512469 A5 JP 2025512469A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- light chain
- seq
- heavy chain
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331716P | 2022-04-15 | 2022-04-15 | |
| US63/331,716 | 2022-04-15 | ||
| PCT/US2023/065764 WO2023201324A1 (en) | 2022-04-15 | 2023-04-14 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512469A JP2025512469A (ja) | 2025-04-17 |
| JP2025512469A5 true JP2025512469A5 (enExample) | 2026-02-02 |
Family
ID=88330384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560676A Pending JP2025512469A (ja) | 2022-04-15 | 2023-04-14 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250249116A1 (enExample) |
| EP (1) | EP4508091A1 (enExample) |
| JP (1) | JP2025512469A (enExample) |
| KR (1) | KR20250004769A (enExample) |
| CN (1) | CN119256008A (enExample) |
| AU (1) | AU2023253710A1 (enExample) |
| CA (1) | CA3248961A1 (enExample) |
| IL (1) | IL315944A (enExample) |
| MX (1) | MX2024012737A (enExample) |
| WO (1) | WO2023201324A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012157167A (ru) * | 2010-07-12 | 2014-08-20 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Полифункциональные антительные конъюгаты |
| JP2023535078A (ja) * | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス，インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
-
2023
- 2023-04-14 CN CN202380034350.7A patent/CN119256008A/zh active Pending
- 2023-04-14 KR KR1020247037612A patent/KR20250004769A/ko active Pending
- 2023-04-14 WO PCT/US2023/065764 patent/WO2023201324A1/en not_active Ceased
- 2023-04-14 EP EP23789168.4A patent/EP4508091A1/en active Pending
- 2023-04-14 CA CA3248961A patent/CA3248961A1/en active Pending
- 2023-04-14 IL IL315944A patent/IL315944A/en unknown
- 2023-04-14 AU AU2023253710A patent/AU2023253710A1/en active Pending
- 2023-04-14 JP JP2024560676A patent/JP2025512469A/ja active Pending
- 2023-04-14 US US18/856,247 patent/US20250249116A1/en active Pending
-
2024
- 2024-10-14 MX MX2024012737A patent/MX2024012737A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025512469A5 (enExample) | ||
| IL315944A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JP2025512468A5 (enExample) | ||
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2024540199A5 (enExample) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| JP2023509793A5 (enExample) | ||
| IL309910A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
| JP2024503609A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| IL320340A (en) | Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene | |
| JP2024527362A5 (enExample) | ||
| JP2024534488A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2023510350A5 (enExample) | ||
| JP2025512464A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| JP2024160045A5 (enExample) | ||
| IL312142A (en) | Muscle targeting complexes for the treatment of dystrophinopathy | |
| IL311507A (en) | Dosing of muscle targeting complexes for the treatment of dystrophinopathy | |
| JP2024525613A5 (enExample) | ||
| IL312170A (en) | Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy | |
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy |